We are building this new website to better deliver information. Find out more. We are building this new website to better deliver information. Find out more.
Let us know what you think.

Updates on 01/08/2016

Human papillomavirus (HPV)

New text noting alternative schedule for 2vHPV in adolescent girls recently registered by the TGA (no change to ATAGI recommendation at this stage).

Pertussis (whooping cough)

Pertussis (also chapters, 4.2 Diphtheria, 4.3 Haemophilus influenzae type b, 4.5 Hepatitis B, 4.14 Poliomyelitis and 4.19 Tetanus, as required)

Clarification of advice, including:

  • On those who are considered close contacts of young infants and those who are considered contacts of others at increased risk from pertussis.
  • On the appropriate action if the dose of dTpa recommended during pregnancy is administered before the third trimester.
  • On the appropriate action for future pertussis vaccines when a mother receives a dose of dTpa post-partum rather than in the third trimester of pregnancy.
  • On the recommended interval between DT-containing vaccines in two contexts: a) standard catch-up and b) maternal pertussis vaccination.
  • That a history of extensive limb swelling after a booster dose of DTPa is not a contraindication to future recommended doses of pertussis-containing vaccine.
  • Factual changes to chapter/s, including:
  • Addition of combination pertussis-containing vaccine, Hexaxim, to the vaccine information box.
  • Updates to Product Information.

Pneumococcal disease

Clarification of advice on the co-administration of trivalent influenza vaccines and 13-valent pneumococcal conjugate vaccines in children, in alignment with update to the Influenza chapter (including new reference).

Clarification of advice on pneumococcal vaccination during pregnancy and breastfeeding.


New text advising on the event of a shortage of the currently registered BCG vaccine and usage of alternative vaccine products.

New sub-section providing advice on the co-administration of BCG vaccine with other vaccines.

New sub-section providing advice on BCG vaccination before or after immunoglobulin or blood product administration.

Yellow fever

Updated ATAGI advice that 10-yearly booster doses are no longer routinely recommended except for groups/circumstances who are specified.

Clarification of advice, including:

  • On the co-administration of yellow fever vaccine with other parenteral live vaccines.
  • On circumstances when vaccination can be considered for pregnant and breastfeeding women.
  • Of groups for whom yellow fever vaccination is contraindicated and appropriate mosquito avoidance advice for such individuals.
  • On the vaccine requirements that need to be meet under updated International Health Regulations (both in Australia and internationally).